Variant strain-based coronavirus vaccines
AssigneeModernaTX, Inc.
InventorsAndrea Carfi, Guillaume Stewart-Jones, Hamilton Bennett, Kai Wu, Darin Edwards, Gwo-Yu Chuang, David Reid
Life of this patent
Estimating the term…
Abstract
The disclosure provides coronavirus mRNA vaccines, including vaccines directed against spike proteins of one or more variant strains of SARS-CoV-2, as well as methods of using the vaccines.
Claims20
-54. (canceled)
A pharmaceutical composition comprising a messenger RNA (mRNA) comprising a nucleotide sequence encoding a SARS-CoV-2 Spike(S) protein, wherein the SARS-CoV-2 S protein comprises:
- (a) at least 10 of the following mutations as compared to SEQ ID NO:18:
- A67V, Δ69-70, T95I, G142D/Δ143-145, Δ211/L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493K, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, and L981F;
- and (b) an amino acid sequence that is at least 97% identical to SEQ ID NO:33, or to an immunogenic fragment thereof;
- wherein the mRNA comprises 1-methyl-pseudouridine substitutions at one or more uridine positions of the mRNA.
A pharmaceutical composition comprising a messenger RNA (mRNA) comprising a nucleotide sequence encoding a SARS-CoV-2 Spike(S) protein, wherein the SARS-CoV-2 S protein comprises:
- (a) at least 10 of the following mutations as compared to SEQ ID NO:18:
- Δ69-70, T95I, G142D, ΔY144, R190S, K417N, N439K, E484K, S477N, T478K, N501Y, D614G, H655Y, and P681H;
- and (b) an amino acid sequence that is at least 97% identical to SEQ ID NO:14, or to an immunogenic fragment thereof;
- wherein the mRNA comprises 1-methyl-pseudouridine substitutions at one or more uridine positions of the mRNA.
Dependencies are inferred from the claim text.